Clinical trials
Cardiomyopathy, Hypertrophic trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
68 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 10 |
| 2024 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 68 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Xijing Hospital | 7 |
| China National Center for Cardiovascular Diseases | 3 |
| Meshalkin Research Institute of Pathology of Circulation | 3 |
| Beijing Institute of Heart, Lung and Blood Vessel Diseases | 2 |
| Hangzhou Valgen Medtech Co., Ltd | 2 |
| Heidelberg University | 2 |
| Region Gävleborg | 2 |
| St. Antonius Hospital | 2 |
| University College, London | 2 |
| University Hospital Birmingham | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiomyopathy, Hypertrophic | 68 |
| Cardiomyopathies | 6 |
| Cardiomyopathy, Dilated | 6 |
| Arrhythmogenic Right Ventricular Dysplasia | 4 |
| Heart Failure | 4 |
| Cardiomyopathy, Restrictive | 3 |
| Fabry Disease | 3 |
| Hypertrophy | 3 |
| Hypertrophy, Left Ventricular | 3 |
| Atrial Fibrillation | 2 |
Trials
Showing 1 to 25 of 68. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.